Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies. Its product candidates include: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism; ACER-801 (osanetant) for the treatment of induced vasomotor symptoms (iVMS); EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS); and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19.